Viking Therapeutics to Attend Upcoming Investor Conferences

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical firm specializing in the development of innovative therapies for metabolic and endocrine conditions, announced its participation in two upcoming investor conferences. The company, listed on NASDAQ as VKTX, is set to attend the 2024 Jefferies Global Healthcare Conference and the Stifel 2nd European Healthcare Summit.

At the Jefferies Global Healthcare Conference, Viking's management will deliver a corporate presentation and engage in one-on-one meetings. The conference will take place on June 5-6, 2024, at the Marriott Marquis in New York, with the presentation scheduled for 10:30 to 10:55 a.m. Eastern Time on June 6. Additionally, a live webcast of the presentation will be accessible through a link on the Viking Therapeutics website, with a replay available post-conference.

The Stifel 2nd European Healthcare Summit will see Viking's management participating in one-on-one meetings. This event is scheduled for June 25-27, 2024, at the InterContinental Lyon Hotel Dieu in Lyon, France.

Viking Therapeutics is actively involved in clinical trials for three of its compounds, aiming to develop first-in-class or best-in-class therapies to improve patient outcomes in metabolic and endocrine disorders. One of their key compounds, VK2809, is a novel, orally available, small molecule selective thyroid hormone receptor beta agonist. It is currently under evaluation in a Phase 2b study for treating biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. Previous Phase 2a trials for non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C have shown significant reductions in LDL-C and liver fat in patients treated with VK2809 compared to those given a placebo.

Another significant candidate in Viking's pipeline is VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed for various metabolic disorders, with data from Phase 1 and Phase 2 trials indicating a promising safety and tolerability profile, along with positive clinical benefits. This compound is also being tested in an oral formulation in a Phase 1 trial.

In the realm of rare diseases, Viking is developing VK0214, an orally available, small molecule selective thyroid hormone receptor beta agonist. This compound is intended for the treatment of X-linked adrenoleukodystrophy (X-ALD), a serious metabolic disorder. VK0214 is currently in a Phase 1b clinical trial targeting patients with the adrenomyeloneuropathy (AMN) form of X-ALD.

Viking Therapeutics holds exclusive worldwide rights to a portfolio of five therapeutic programs, including VK2809 and VK0214, licensed from Ligand Pharmaceuticals Incorporated. The company leverages its specialized knowledge in metabolism to pioneer therapeutic solutions that aim to enhance the quality of life for patients suffering from these complex disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!